Chronic kidney disease is characterized by impaired kidney function, leading to the inefficient filtration of blood, resulting in the accumulation of excess fluid and waste in the body. Common causes include diabetes, high blood pressure, and obesity. Managing this condition requires ongoing care and may progress to end-stage renal failure, necessitating dialysis or transplantation.
Key diagnostic tests for chronic kidney disease include blood tests, urine tests, imaging tests, and kidney biopsy. Blood tests involve the examination of a blood sample for medical evaluation. Treatment modalities encompass drugs, dialysis, kidney transplants, ACE inhibitors, and other interventions. These drugs can be administered through oral, intravenous, and subcutaneous routes, catering to various end-users such as hospitals, clinics, ambulatory surgery centers (ASCS), dialysis centers, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The chronic kidney disease market research report is one of a series of new reports from The Business Research Company that provides chronic kidney disease market statistics, including the chronic kidney disease industry global market size, regional shares, competitors with a chronic kidney disease market share, detailed chronic kidney disease market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic kidney disease industry. This chronic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The chronic kidney disease market size has grown strongly in recent years. It will grow from $70.65 billion in 2024 to $74.87 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to hypertension and diabetes epidemic, aging population, unhealthy lifestyles, healthcare access disparities, medical advances.
The chronic kidney disease market size is expected to see strong growth in the next few years. It will grow to $95.43 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to healthcare policy focus, precision medicine development, rise in obesity rates, growth in chronic diseases, improved healthcare access. Major trends in the forecast period include early screening campaigns, telemedicine and remote monitoring, patient empowerment programs, community-based care initiatives, nutritional therapy integration.
The forecast of 6.3% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. nephrology by driving up the cost of phosphate binders and renal anemia medications sourced from France and Israel, exacerbating dialysis dependency risks and increasing kidney care program expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The escalating prevalence of kidney disease is poised to drive the expansion of the chronic kidney disease (CKD) market. Kidney diseases encompass various conditions that affect the kidneys' function and structure, often necessitating medication to manage symptoms, control blood pressure, and minimize protein loss. As per data from the Centers for Disease Control and Prevention in July 2022, approximately 15% or 37 million individuals in the US grapple with kidney disease, underscoring the surge in its prevalence. Consequently, this mounting prevalence is a key driver propelling the growth trajectory of the chronic kidney disease market.
The burgeoning aging population is anticipated to contribute significantly to the chronic kidney disease market's expansion. The term 'aging population' denotes a demographic trend marked by a higher proportion of elderly individuals within a society or populace. This demographic shift is closely associated with an elevated reliance on chronic kidney disease (CKD) management due to the rising incidence of kidney-related issues among the elderly. With age, the risk of kidney ailments, including CKD, tends to escalate. Notably, the World Health Organization's October 2022 report highlights a rapid growth projection for the global population aged 60 years and older, expected to double by 2050, reaching an estimated 2.1 billion individuals. Hence, the increasing aging demographic is a significant factor propelling the chronic kidney disease market's growth trajectory.
Product innovation stands out as a pivotal trend gaining momentum in the chronic kidney disease market. Companies navigating this sector are dedicating efforts toward developing innovative products to fortify their market presence. For example, Bayer, a Germany-based biotechnology and pharmaceutical entity, unveiled Kerendia (finerenone) in August 2022. This groundbreaking medicine, categorized as a non-steroidal, selective mineralocorticoid receptor antagonist, offers a novel approach to decelerate chronic kidney disease progression among diabetic patients. Its distinctive mechanism involves the blocking of mineralocorticoid receptor (MR) overactivation, thereby addressing factors contributing to CKD progression and associated cardiovascular damage, setting it apart from existing treatments.
Major players in the chronic kidney disease market are engaging in strategic partnerships to explore the safety and efficacy of an enhanced Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. These strategic partnerships involve collaborations where companies harness each other's strengths and resources to achieve mutual benefits. As an illustration, in June 2023, AWAK Technologies Pte Ltd., a Singapore-based medical technology firm, forged a partnership with Singapore General Hospital Pte Ltd. (SGH), an academic health science center and hospital entity in Singapore. This collaboration aims to revolutionize kidney disease diagnosis, treatment, and management by spearheading the development and evaluation of AWAK PD, a wearable and ultra-portable peritoneal dialysis (PD) system. This innovative system allows end-stage kidney disease patients the flexibility to undergo dialysis at home and while on the move, thereby enhancing their quality of life and treatment convenience.
In January 2023, the US-based biopharmaceutical company AstraZeneca Pharmaceuticals LP successfully acquired CinCor Pharma Inc. for $1.8 billion. Through this acquisition, AstraZeneca aims to enrich its cardiorenal pipeline by incorporating CinCor's candidate medicine, baxdrostat (CIN-107). Baxdrostat is an aldosterone synthase inhibitor (ASI) designed for blood pressure control in the treatment of resistant hypertension. CinCor Pharma Inc., based in the US, is a clinical-stage biopharmaceutical company specializing in the development of products for the treatment of resistant and uncontrolled hypertension, as well as chronic kidney disease.
Major companies operating in the chronic kidney disease market include Pfizer Inc, Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceuticals Ltd., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk AS, Siemens Healthineers AG, AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Beckman Coulter Inc., Kissei Pharmaceutical Co. Ltd., Akebia Therapeutics Inc., Mission Therapeutics Ltd., Tricida Inc., Regulus Therapeutics Inc., Goldfinch Bio Co, Alio Inc., Monogram Health, Strive Health, Maze Therapeutics, ProKidney Corp
North America was the largest region in the chronic kidney disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the chronic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The chronic kidney disease market consists of revenues earned by entities by providing peritoneal dialysis, in-center hemodialysis, and home hemodialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic kidney disease market also includes sales such as captopril, enalapril, finerenone, and fosinopril used during the treatment procedure. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Chronic Kidney Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on chronic kidney disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for chronic kidney disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chronic kidney disease market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Diagnosis: Blood Test; Urine Test; Imaging Test; Kidney Biopsy
- 2) By Treatment: Drugs; Dialysis; Kidney Transplant; ACE Inhibitors; Blood Test; Other Treatments
- 3) By Route of Administration: Oral; Intravenous; Subcutaneous
- 4) By End-User: Hospital And Clinics; Ambulatory Surgery Centers (ASCs); Dialysis Centers; Other End-Users
- Subsegments:
- 1) By Blood Test: Serum Creatinine Test; Glomerular Filtration Rate (GFR) Test; Blood Urea Nitrogen (BUN) Test; Electrolyte Tests
- 2) By Urine Test: Urinalysis; 24-hour Urine Collection; Urine Protein Test; Urine Albumin-To-Creatinine Ratio (ACR)
- 3) By Imaging Test: Ultrasound; CT Scan; MRI; X-ray
- 4) By Kidney Biopsy: Percutaneous Kidney Biopsy; Open Kidney Biopsy; Laparoscopic Kidney Biopsy
- Companies Mentioned: Pfizer Inc; Johnson and Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG; Novartis International AG; Sanofi SA; Bristol-Myers Squibb Company; Abbott laboratories Inc.; GlaxoSmithKline PLC; Takeda Pharmaceuticals Ltd.; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Amgen Inc.; Novo Nordisk AS; Siemens Healthineers AG; AstraZeneca Pharmaceuticals LP; Teva Pharmaceutical Industries Ltd.; Beckman Coulter Inc.; Kissei Pharmaceutical Co. Ltd.; Akebia Therapeutics Inc.; Mission Therapeutics Ltd.; Tricida Inc.; Regulus Therapeutics Inc.; Goldfinch Bio Co; Alio Inc.; Monogram Health; Strive Health; Maze Therapeutics; ProKidney Corp
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Chronic Kidney Disease Market Characteristics
3. Chronic Kidney Disease Market Trends And Strategies
4. Chronic Kidney Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Chronic Kidney Disease Growth Analysis And Strategic Analysis Framework
- 5.1. Global Chronic Kidney Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Chronic Kidney Disease Market Growth Rate Analysis
- 5.4. Global Chronic Kidney Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Chronic Kidney Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Chronic Kidney Disease Total Addressable Market (TAM)
6. Chronic Kidney Disease Market Segmentation
- 6.1. Global Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Blood Test
- Urine Test
- Imaging Test
- Kidney Biopsy
- 6.2. Global Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Drugs
- Dialysis
- Kidney Transplant
- ACE Inhibitors
- Blood Test
- Other Treatments
- 6.3. Global Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Intravenous
- Subcutaneous
- 6.4. Global Chronic Kidney Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital and Clinics
- Ambulatory Surgery Centers (ASCs)
- Dialysis Centers
- Other End-Users
- 6.5. Global Chronic Kidney Disease Market, Sub-Segmentation Of Blood Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Serum Creatinine Test
- Glomerular Filtration Rate (GFR) Test
- Blood Urea Nitrogen (BUN) Test
- Electrolyte Tests
- 6.6. Global Chronic Kidney Disease Market, Sub-Segmentation Of Urine Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Urinalysis
- 24-hour Urine Collection
- Urine Protein Test
- Urine Albumin-To-Creatinine Ratio (ACR)
- 6.7. Global Chronic Kidney Disease Market, Sub-Segmentation Of Imaging Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ultrasound
- CT Scan
- MRI
- X-ray
- 6.8. Global Chronic Kidney Disease Market, Sub-Segmentation Of Kidney Biopsy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Percutaneous Kidney Biopsy
- Open Kidney Biopsy
- Laparoscopic Kidney Biopsy
7. Chronic Kidney Disease Market Regional And Country Analysis
- 7.1. Global Chronic Kidney Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Chronic Kidney Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Chronic Kidney Disease Market
- 8.1. Asia-Pacific Chronic Kidney Disease Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Chronic Kidney Disease Market
- 9.1. China Chronic Kidney Disease Market Overview
- 9.2. China Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Chronic Kidney Disease Market
- 10.1. India Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Chronic Kidney Disease Market
- 11.1. Japan Chronic Kidney Disease Market Overview
- 11.2. Japan Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Chronic Kidney Disease Market
- 12.1. Australia Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Chronic Kidney Disease Market
- 13.1. Indonesia Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Chronic Kidney Disease Market
- 14.1. South Korea Chronic Kidney Disease Market Overview
- 14.2. South Korea Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Chronic Kidney Disease Market
- 15.1. Western Europe Chronic Kidney Disease Market Overview
- 15.2. Western Europe Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Chronic Kidney Disease Market
- 16.1. UK Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Chronic Kidney Disease Market
- 17.1. Germany Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Chronic Kidney Disease Market
- 18.1. France Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Chronic Kidney Disease Market
- 19.1. Italy Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Chronic Kidney Disease Market
- 20.1. Spain Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Chronic Kidney Disease Market
- 21.1. Eastern Europe Chronic Kidney Disease Market Overview
- 21.2. Eastern Europe Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Chronic Kidney Disease Market
- 22.1. Russia Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Chronic Kidney Disease Market
- 23.1. North America Chronic Kidney Disease Market Overview
- 23.2. North America Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Chronic Kidney Disease Market
- 24.1. USA Chronic Kidney Disease Market Overview
- 24.2. USA Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Chronic Kidney Disease Market
- 25.1. Canada Chronic Kidney Disease Market Overview
- 25.2. Canada Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Chronic Kidney Disease Market
- 26.1. South America Chronic Kidney Disease Market Overview
- 26.2. South America Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Chronic Kidney Disease Market
- 27.1. Brazil Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Chronic Kidney Disease Market
- 28.1. Middle East Chronic Kidney Disease Market Overview
- 28.2. Middle East Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Chronic Kidney Disease Market
- 29.1. Africa Chronic Kidney Disease Market Overview
- 29.2. Africa Chronic Kidney Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Chronic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Chronic Kidney Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Chronic Kidney Disease Market Competitive Landscape And Company Profiles
- 30.1. Chronic Kidney Disease Market Competitive Landscape
- 30.2. Chronic Kidney Disease Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson and Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Chronic Kidney Disease Market Other Major And Innovative Companies
- 31.1. Novartis International AG
- 31.2. Sanofi SA
- 31.3. Bristol-Myers Squibb Company
- 31.4. Abbott Laboratories Inc.
- 31.5. GlaxoSmithKline PLC
- 31.6. Takeda Pharmaceuticals Ltd.
- 31.7. Eli Lilly and Company
- 31.8. Boehringer Ingelheim International GmbH
- 31.9. Amgen Inc.
- 31.10. Novo Nordisk AS
- 31.11. Siemens Healthineers AG
- 31.12. AstraZeneca Pharmaceuticals LP
- 31.13. Teva Pharmaceutical Industries Ltd.
- 31.14. Beckman Coulter Inc.
- 31.15. Kissei Pharmaceutical Co. Ltd.
32. Global Chronic Kidney Disease Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Chronic Kidney Disease Market
34. Recent Developments In The Chronic Kidney Disease Market
35. Chronic Kidney Disease Market High Potential Countries, Segments and Strategies
- 35.1 Chronic Kidney Disease Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Chronic Kidney Disease Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Chronic Kidney Disease Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
